Glucose control during breakthrough SARS-CoV-2 infections in vaccinated patients with type 1 diabetes
Authors' conclusion
Breakthrough SARS-CoV-2 infection did not worsen glycemic control in vaccinated people with T1D.
Study context
- Population
- Continuous Glucose Monitoring (CGM) users with T1D vaccinated against COVID-19 who had a breakthrough SARS-CoV-2 infection between November 2021 and February 2022
- Participants
- 106 users
- Exposure
- CGM metrics 14 days before vs during vs after breakthrough SARS-CoV-2 infection
- Outcome
- Trend of CGM-derived glycemic control metrics during SARS-CoV-2 infection
Main finding
As reported in the abstract
GMI · Time 3 vs Time 2
P = 0.006
Observational data: associations, not effects.
Further findings
| Outcome | Time 2 | Time 3 | P value |
|---|---|---|---|
| TIR · Time 3 vs Time 2Significant increase at Time 3 | 52.1 ± 19.7 % | 54.6 ± 20.4 % | P = 0.026 |
- Glucose SD and CV · Time 3 and Time 2 vs Time 1 · significant reduction
- P < 0.001
- Glucose SD and CV · Time 3 and Time 2 vs Time 1 · significant reduction
- P < 0.001
Glucose SD and CV · Time 3 and Time 2 vs Time 1
- Associated with significant changes of mean glucose, TBR level 1 and total daily insulin doses
Original publication
Glucose control during breakthrough SARS-CoV-2 infections in vaccinated patients with type 1 diabetes. Diabetes Res Clin Pract. Published 9 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →